Quince Therapeutics Approves Key Proposals at Annual Meeting

The latest update is out from Quince Therapeutics ( (QNCX) ).

On June 4, 2025, Quince Therapeutics, Inc. held its Annual Meeting of Stockholders online, where several key proposals were approved. These included the election of three Class III directors, an amendment to increase authorized shares from 100 million to 250 million, a reverse stock split at a one-for-ten ratio, ratification of BDO USA, P.C. as the accounting firm for 2025, and approval of executive compensation.

The most recent analyst rating on (QNCX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.

Spark’s Take on QNCX Stock

According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.

Quince Therapeutics faces substantial financial challenges with no revenue, consistent losses, and negative cash flows, severely impacting its financial performance score. Technical analysis provides mixed signals, with some indicators suggesting potential momentum but overall bearish trends. Valuation remains unattractive due to the negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data limits further insights.

To see Spark’s full report on QNCX stock, click here.

More about Quince Therapeutics

Average Trading Volume: 286,685

Technical Sentiment Signal: Sell

Current Market Cap: $47.74M

For a thorough assessment of QNCX stock, go to TipRanks’ Stock Analysis page.